BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma Clinical Trial

Official title:

A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BCMA-targeted LCAR-BCDR Cells Product in Patients With Relapsed/Refractory Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05376345
• Other study ID #: BM2L202103
• Status: Recruiting
• Phase: Phase 1
• Start date: September 1, 2022
• Est. completion date: September 2026

Study information

• Verified date: September 2023
• Source: Shanghai Changzheng Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, single-arm, open-label, dose-finding and dose-expansion study that evaluates the safety, tolerability, PK, and anti-tumor efficacy of LCAR-BCDR cell preparations in relapsed/refractory multiple myeloma subjects who received adequate standard therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 32
• Est. completion date: September 2026
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The subject voluntarily participates in the clinical study; Fully understand and be Informed of the study and sign the Informed consent (Informed Consent Form, ICF); Willing to follow and able to complete all test procedures; Informed consent must be obtained before initiating any tests or procedures related to the study that are not part of the standard treatment of the subject's disease;

2. Subjects = 18 years of age.

3. Documented initial diagnosis of MM according to IMWG diagnostic criteria.

4. Presence of measurable disease at screening.

5. Received a PI and an IMiD (except thalidomide).

6. Received at least 3 prior lines of therapy for multiple myeloma, undergone at least 1 complete cycle of treatment for each line, unless progressive disease (PD) was documented by IMWG criteria as the best response to the regimen. Also, subjects refractory or intolerant to any PI and any IMiD in their previous treatment afterwards are eligible.

7. Expected survival = 3 months.

8. Clinical laboratory values meet screening visit criteria

9. Fertile women must be negative using a highly sensitive serum pregnancy test (ß human chorionic gonadotropin [ß -HCG]) at screening time and before initial treatment with cyclophosphamide and fludarabine;

Exclusion Criteria:

1. No response to prior BCMA-targeted CAR-T therapy (except in subjects who relapsed after CR to prior CAR-T treatment).

2. Prior treatment with any antibody targeting BCMA.

3. Diagnosed or pretreated for an invasive malignancy other than multiple myeloma.

4. Prior anti-tumor treatment (before pretreatment) with insufficient washout period.

5. Known active, or prior history of central nervous system (CNS) involvement, or clinical signs of membrane/spinal membrane involvement of multiple myeloma.

6. Positive of any hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), human immunodeficiency virus antibody (HIV-Ab) at the time of screening.

7. Serious underlying medical conditions

8. Male subjects who have a birth plan during the study period or within 1 year after the study treatment.

9. Female subjects who are pregnant, breast-feeding, or plan to become pregnant during the study period or within 1 year after the study treatment.

10. The investigator considered that the subjects were not suitable for any conditions of participation in the study.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Relapsed/Refractory Multiple Myeloma

Intervention

Biological:
• LCAR-BCDR cells product
Before treatment with LCAR-BCDR cells, subjects will receive a conditioning regimen

Locations

Country	Name	City	State
China	Beijing Gobroad Boren Hospital	Beijing	Beijing
China	Zhejiang Provincial People's Hospital	Hangzhou	Zhejiang
China	Shanghai Changzheng Hospital	Shanghai
China	Shanghai Fourth People's Hospital Affiliated to Tongji University	Shanghai
China	Institute of Hematology & Blood Diseases Hospital	Tianjin
China	The First Affiliated Hospital of Wenzhou Medical University	Wenzhou

Sponsors (2)

Lead Sponsor	Collaborator
Weijun Fu	Nanjing Legend Biotech Co.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence, severity, and type of treatment-emergent adverse events (TEAEs)	An adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which does not necessarily have a causal relationship with the treatment.	Minimum 2 years after LCAR-BCDR infusion (Day 1)
Primary	Recommended Phase 2 dose (RP2D) finding	RP2D established through ATD+BOIN design	30 days after LCAR-BCDR infusion (Day 1)
Primary	CAR positive T cells in peripheral blood and bone marrow	CAR positive T cells in peripheral blood and bone marrow after LCAR-BCDR infusion	Minimum 2 years after LCAR-BCDR infusion (Day 1)
Primary	CAR transgene levels in peripheral blood and bone marrow	CAR transgene levels in peripheral blood and bone marrow after LCAR-BCDR infusion	Minimum 2 years after LCAR-BCDR infusion (Day 1)
Secondary	Overall Response Rate (ORR)	The ORR is defined as the percentage of participants who achieve partial response (PR) or better according to international myeloma working group (IMWG) criteria.	Minimum 2 years after LCAR-BCDR infusion (Day 1)
Secondary	Progression-free survival (PFS)	Progression Free Survival (PFS) is defined as the time from the date of first infusion of the LCAR-BCDR to the first documented disease progression (according to IMWG criteria) or death (due to any cause), whichever occurs first	Minimum 2 years after LCAR-BCDR infusion (Day 1)
Secondary	Overall Survival (OS)	Overall Survival (OS) is defined as the time from the date of first infusion of LCAR-AIO to death of the subject	Minimum 2 years after LCAR-BCDR infusion (Day 1)
Secondary	Incidence of anti-LCAR-BCDR antibody	Venous blood samples will be collected to measure LCAR-BCDR positive cell concentrations and the transgenic level of LCAR-BCDR, at the time points when anti-LCAR-BCDR antibody serum samples are evaluated	Minimum 2 years after LCAR-BCDR infusion (Day 1)